Wang Ting, Jiang Chang-Xin, Li Ying, Liu Xin
Department of Pathology, Tianjin Medical University, Tianjin 300070, China.
Zhonghua Bing Li Xue Za Zhi. 2009 Dec;38(12):824-8.
To study the roles of matrix metalloproteinases-9 (MMP-9), tissue inhibitor of metalloproteinase-1 (TIMP-1), vascular endothelial growth factor (VEGF) and transforming growth factor β-1 (TGFβ-1) in differentiation, invasiveness and metastatic potential of papillary carcinoma and follicular carcinoma of thyroid.
Eighty-five cases of papillary thyroid carcinoma and 59 cases of follicular thyroid carcinoma were enrolled into the study. Immunohistochemistry using EnVision method was carried out for assessment of the expression of MMP-9, TIMP-1, VEGF and TGFβ-1 in the tumor tissue.
MMP-9, TIMP-1, VEGF and TGFβ-1 were expressed in the cytoplasm of tumor cells. The positivity rates of MMP-9, TIMP-1, VEGF and TGFβ-1 in papillary thyroid carcinoma (83.5%, 81.2%, 90.6% and 75.3%, respectively) were similar to or lower than those in follicular thyroid carcinoma (93.2%, 86.4%, 89.9% and 78.0%, respectively). The expression rates in papillary thyroid carcinoma with lymph node metastasis were also higher than those in tumors without lymph node metastasis. The expression rates of MMP-9, VEGF and TGFβ-1 in poorly-differentiated follicular thyroid carcinoma were higher than those in well-differentiated follicular thyroid carcinoma. The expression of TIMP-1 however showed a negative correlation with the tumor cell differentiation. In general, the expression of VEGF and MMP-9 was higher than that of TIMP-1 and TGFβ-1 in papillary thyroid carcinoma and follicular thyroid carcinoma.
Immunohistochemical detection of MMP-9, TIMP-1, VEGF and TGFβ-1 expression may carry clinical significance in evaluating the degree of differentiation, invasiveness, metastatic potential and prognosis of papillary thyroid carcinoma and follicular thyroid carcinoma.
研究基质金属蛋白酶-9（MMP-9）、金属蛋白酶组织抑制剂-1（TIMP-1）、血管内皮生长因子（VEGF）和转化生长因子β-1（TGFβ-1）在甲状腺乳头状癌和滤泡状癌的分化、侵袭及转移潜能中的作用。
本研究纳入85例甲状腺乳头状癌和59例甲状腺滤泡状癌患者。采用EnVision法进行免疫组织化学检测，以评估肿瘤组织中MMP-9、TIMP-1、VEGF和TGFβ-1的表达情况。
MMP-9、TIMP-1、VEGF和TGFβ-1在肿瘤细胞的细胞质中表达。甲状腺乳头状癌中MMP-9、TIMP-1、VEGF和TGFβ-1的阳性率分别为83.5%、81.2%、90.6%和75.3%，与甲状腺滤泡状癌（分别为93.2%、86.4%、89.9%和78.0%）相似或低于后者。有淋巴结转移的甲状腺乳头状癌的表达率也高于无淋巴结转移的肿瘤。低分化甲状腺滤泡状癌中MMP-9、VEGF和TGFβ-1的表达率高于高分化甲状腺滤泡状癌。然而，TIMP-1的表达与肿瘤细胞分化呈负相关。总体而言，甲状腺乳头状癌和滤泡状癌中VEGF和MMP-9的表达高于TIMP-1和TGFβ-1。
免疫组织化学检测MMP-9、TIMP-1、VEGF和TGFβ-1的表达可能对评估甲状腺乳头状癌和滤泡状癌的分化程度、侵袭性、转移潜能及预后具有临床意义。
